The Multiple Myeloma Channel on VJHemOnc is an independent medical education platform, supported with funding from BMS (Gold) and Legend Biotech (Bronze). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
ASH 2025 | The latest updates in the pre-malignant space: the PROMISE study and the potential of immunotherapy
Irene Ghobrial, MD, Dana-Farber Cancer Institute, Boston, MA, discusses the latest updates in the pre-malignant space. She highlights the PROMISE study (NCT03689595), a screening study for individuals at risk of developing multiple myeloma, as well as the potential of immunotherapy in the treatment of smoldering myeloma. This interview took place at the 67th ASH Annual Meeting and Exposition, held in Orlando, FL.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
